Overview

The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)

Status:
Completed
Trial end date:
2016-02-29
Target enrollment:
Participant gender:
Summary
This study aims to determine whether MK-8291 is effective in reducing pain in participants with post-herpetic neuralgia (PHN) with allodynia. The primary hypothesis is that when compared to placebo, treatment with MK-8291 reduces the change from Baseline in participant-reported pain intensity by 1 on an 11-point numeric rating scale.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.